Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Phase 1/2 of dual-BCMA/CD19 CAR T w/asymmetric 4-1BB/CD28-YMFM costim in RRMM shows 95% ORR, 93.3% metabolic response in EMD pts & lesion-infiltrating CAR T cells w/ CCL3/4 expression & apoptotic & necroptotic programs.”
Title: Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease
Authors: David F. Moreno, Ferran Nadeu, Marta Casado-Peláez, Caterina Mata, Ian Márquez-López, Marco A. Fernández, Sergi Vaqué, Elena Medina, Helena Llobregat, Marta Garrote, Joan Mañé, Oriol Cardús, Luis Gerardo Rodríguez-Lobato, Anna de Daniel, María Teresa Cibeira, Theo Gremen Oliveira, Elizaveta Kulaeva, Ester Lozano, Dolors Colomer, Laura Rosiñol, Ruben van Boxtel, Manel Esteller, Carlos Fernández de Larrea
You can read the full article on Journal of Hematology & Oncology.

You can find other articles featuring Robert Orlowski on OncoDaily.